Exagen Seeks FDA Nod on Breast Cancer Test Kit
Exagen Diagnostics Inc. is petitioning the U.S. Food and Drug Administration for approval of a DNA-based test that might enable physicians to more accurately predict incidences of breast cancer recurrence, the company revealed Thursday. The product, eXagenBC, is the first of six currently in development and can be performed and analyzed at several qualified laboratories. Based in Albuquerque, N.M., Exagen develops genomic marker-based diagnostic kits and accompanying analytical software. Additional products in the pipeline will help diagnose and predict issues related to gastroenterology, infectious diseases and general medicine. Exagen is venture backed by Tullis Dickerson & Co., vSpring Capital, and Wasatch Venture Fund.
posted on Thursday, April 5, 2007
Related companies:
Exagen Diagnostics
Related stories:
> RCP Diagnostics Licenses Technology
> Exagen Diagnostics Names COO
> Myriad Genetics Buys Sividon Diagnostics
> Provista Diagnostics Raises $5.0M
> Exagen Raises $5.3M For Diagnostic Tests
Techrockies.com Home